Skip to main content

Advertisement

Log in

Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)

  • MEDICAL GENETICS
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective medical treatment is available. We treated three boys with severe OI type III and vertebral deformities for 5–7 years with continuous oral administration of the bisphosphonate, olpadronate. Treatment resulted in a decreased number of bone fractures, an increased calcification of the long bones and an amelioration of vertebral shape. No side-effects were encountered.

Conclusion These preliminary but long-term obser- vations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Bisphosphonates may be promi- sing drugs for children with OI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 20 November 1996 / Accepted: 25 February 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landsmeer-Beker, E., Massa, G., Maaswinkel-Mooy, P. et al. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156, 792–794 (1997). https://doi.org/10.1007/s004310050715

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004310050715

Navigation